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(57) ABSTRACT 
A method of supplementing a diet and ameliorating oxidative 
stress in a mammal includes administering a pharmaceuti 
cally effective amount of lipid soluble, hydrophobic active 
compounds having a chemical structure: 
R1 
/ \ 
R2 R2 
wherein R1 is an aromatic backbone and R2 is a sulfur 
containing ligand. Through formation of disul?de link 
ages other moieties can be attached to R2 converting the 
hydrophobic base into a water soluble entity, for ease of 
delivery, which can be reconverted back to the original 
compound by biochemical reduction in the blood 
stream. 
45 Claims, No Drawings 
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METHOD OF AMELIORATING OXIDATIVE 
STRESS AND SUPPLEMENTING THE DIET 
This application is a continuation-in-part (CIP) of US. 
patent application Ser. No. 12/731,415 ?led on 25 Mar. 2010, 
the full disclosure of Which is incorporated herein by refer 
ence. 
TECHNICAL FIELD 
The present invention relates generally to the ?eld of 
dietary supplements for mammals and, more particularly, to 
methods of supplementing a diet, removing heavy metals and 
other toxins and ameliorating oxidative stress. 
BACKGROUND OF THE INVENTION 
Heavy metals such as mercury, lead, cadmium and silver 
can bind to proteins on the proteins’ incorporated cysteine 
residues Which contain sulfhydryl or iSH groups. This 
abnormally inhibits or activates their biological properties. 
Further, a heavy metal binding speci?c proteins can induce 
damage that leads to overproduction or leakage of reactive 
oxygen species (ROSs) from their normal locations. These 
ROSs, mostly produced in the mitochondria of the cells of the 
body, then react With protein, nucleic acid (DNA, RNA) and 
lipid molecules in the healthy cell changing their property/ 
chemistry and leading to unhealthy cells that may die or at 
least be unable to defend themselves from other stress factors 
such as viral infection. In addition to heavy metals there are 
many other chemical toxicants that can induce oxidative 
stress including, for example, radiation toxicity, acetomi 
nophen and dioxin. Further, it is Well knoWn that the oxidation 
of reduced glutathione (GSH) to oxidiZed glutathione (G-Si 
S-G) is one of the ?rst biochemical signals for apoptotic cell 
death (or programmed cell death). The inadvertent oxidation 
of GSH by toxin produced ROSs could lead to increased 
GSSG and cell death also. In the healthy body GSH accom 
plishes protection against heavy metal toxicity, organic toxins 
and hydroxyl free radical damage due to its chemical ability 
to; (l) chelate heavy metals, (2) its use by the enZyme glu 
tathione-S-transferase (GST) to produce GS-toxin complexes 
that are actively removed from the intracellular location into 
the blood and then actively removed from the blood by GS 
toxin receptors in the bilary transport system of the liver and 
into the bile and feces and (3) GSH’s ability to scavenge and 
eliminate hydroxyl free radicals. 
It is Well knoWn that excess exposures to heavy metals, 
above the capacity of the normal cellular GSH capability to 
bind and remove, inhibit the enzymes involved in the synthe 
sis of GSH and the recovery of oxidiZed GSH from GSSG 
(oxidiZed glutathione) leading to decreased GSH levels that 
are identi?ed as oxidative stress. Also, such heavy metal 
excesses lead to an overproduction of free radicals by the 
mitochondrial and further oxidiZes GSH to GSSG and 
decreases the cells ability to remove toxins (organic and 
heavy metals) by the loWering of the intracellular concentra 
tion of GSH. Therefore, an ideal Way to recover GSH levels 
Would be to develop a non-toxic compound With membrane 
penetrating abilities, heavy metal binding properties and 
reactive oxygen species scavenging properties that Were 
superior to GSH. 
With these properties a Well designed compound With both 
heavy metal chelation properties and antioxidant properties 
could; (I) easily penetrate cell membranes and the blood 
brain barrier, (2) bind heavy metals preventing their inhibi 
tion of enzymes needed to synthesiZe GSH and recover GSH 
m 
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from GSSG, (3) decrease free radical formation by reversing 
heavy metal inhibition of the mitochondrial electron transport 
system, and (4) scavenge hydroxyl free radicals preventing 
oxidation of naturally produced GSH to GSSG. With these 
four properties such a compound could dramatically increase 
intracellular GSH and reduce free radical damage and alloW 
the cells to recover to a normal state. In addition, the increase 
in intracellular GSH Would alloW GST to remove organic 
toxins built up during periods of toxicity and enhance the 
ability of the P-450 system to further detoxify the subject 
using the natural system. For example, it is Well knoWn that 
GSH is directly involved in binding to components of viral 
replication systems inhibiting viral replication. LoW GSH 
levels are a major risk factor for several viral infections and 
high GSH seems involved in reversing and preventing such 
viral infections. 
In order to medically prevent or reduce the oxidative stress 
problem identi?ed as loW GSH levels, heavy metals must be 
excreted by natural means or complexed by medically based 
chelator compounds that render them biologically unavail 
able to elicit their toxic effects. To effect this removal and 
tightly bind the heavy metals, the treating compound must be 
able to effectively remove the metal from the single sulfur 
residue and bind it more tightly than is capable With only one 
sulfur to metal bond. That is, the compound must make at 
least tWo intramolecular sulfur to metal bonds to be able to 
prevent subsequent reaction or exchange of the complexed 
metal With other biomolecules. This requires that the chelat 
ing molecule contain at least tWo sulfhydryls that are one 
extended arms that alloW for extended freedom of rotation 
and movement of the sulfhydryls so that the most stable 
orientiation for binding the heavy metal can be obtained. For 
example, the ideal chelating compound must have degrees of 
freedom of rotation and movement of the sulfur bonds to be 
able to bind different heavy metals that have different coor 
dination chemistries (e.g. different bond angles that confer 
tighter bonding). For example, Hg2+ and Pb2+ both can form 
tWo bonds With iSH groups, but the most stable binding of 
each metal Would have different bond angles. 
To be effective at treating both intracellular heavy metal 
toxicity and radiation toxicity as Well as oxidative stress asso 
ciated thereWith, the treating compound has to be able to cross 
the cellular membrane With ef?ciency and, if the brain is 
involved, the treating compound must be able to cross the 
blood brainbarrier. In order to be able to do this the compound 
has to be quite hydrophobic in nature in order to be able to 
pass through the lipid bilayer of the cell membrane to reach 
the site of heavy metal binding and intercept the ROS pro 
duced by the mitochondria before they react and damage 
cellular constituents. Further, the ideal treating compound 
must be of very loW toxicity to cells and not disrupt mem 
branes or biological pathWays and it should not be involved in 
any natural metabolism that Would destroy its physical char 
acter. In addition, the treating compound must be e?iciently 
excreted from all tissues of the body in a non-toxic form. For 
example, if the treating compound binds mercury cation 
(Hg2+) it must carry this metal ion out of the body and not 
distribute it to other organs such as the kidney. 
The ideal treatment compound must also exhibit stability 
to air oxidation and breakdoWn so that the treating compound 
can be effectively stored and packaged for delivery to the 
patient in original, active form. The treating compound ide 
ally must also be suited for ease of administration to a patient. 
Further, the treating compound must not deplete the body of 
essential metals such as Zinc and copper. In addition, it should 
also have an adequately long plasma half-life such that it is 
US 8,426,368 B2 
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possible to take eight hours rest and not have the treating 
compound signi?cantly depleted from the plasma and tissues. 
The present invention relates to methods of supplementing 
the diet of a mammal, removing heavy metals and other toxins 
from a mammal and ameliorating undesirable oxidative stress 
in a mammal using a single molecule With cell membrane 
penetrating abilities, metal chelation and oxygen radical 
scavenging properties, and non-toxic character. To aid in 
intraveneous delivery, some hydrophobic (lipophilic) com 
pounds are made to be hydrophilic by formation of hydro 
philic (Water soluble) analogs via attachment by disul?de 
linkages that are converted after delivery by the body’ s reduc 
ing capability back to the hydrophobic state. Other com 
pounds have the reverse ability in that they are delivered as 
hydrophobic esters and converted intracellular, by Well 
knoWn esterases, into Water soluble, hydrophilic compounds 
that are more excretable through the kidneys. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention as 
described herein, a method of supplementing a diet of a 
mammal is provided. That method comprises: administering 
to said mammal a pharmaceutically effective amount of a 
compound having a chemical formula: 
Where R1: 
4 
20 
|\ 
/ 
N 
25 
CH3 
.0 / m 
O O 
Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys 
65 teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
US 8,426,368 B2 
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acetate or chloroacetate and n:2-4. The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. 
In accordance With yet another aspect of the present inven 
tion, a method to remove heavy metals and toxins from a 
mammal comprises: administering to said mammal a phar 
maceutically effective amount of a compound having a 
chemical formula: 
Where R1: 
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-continued 
Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n:2 -4. The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. 
In accordance With yet another aspect of the present inven 
tion a method is provided for relieving oxidative stress in a 
mammal. That method comprises: administering to said 
mammal a pharmaceutically effective amount of a compound 
having a chemical formula: 
US 8,426,368 B2 
m 
Where R1: 
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50 
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-continued 
0 
/\\N/ and —N 
H 
N 
/S\ - O/ \O , 
and 
——O 
Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n:2 —4. The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. 
In accordance With yet another aspect of the present inven 
tion, a pharmaceutical composition is provided comprising: 
a pharmaceutically effective amount of a compound hav 
ing a chemical formula: 
Where R1: 
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-continued 
H 
N 
Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n:2-4; The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. and 
a pharmaceutically acceptable excipient. 
In accordance With yet another aspect of the present inven 
tion, a pharmaceutical composition is provided comprising: 
betWeen about 99.5 and about 5 Weight percent of a phar 
maceutically effective amount of a compound having a 
chemical formula: 
Where R1: 
\ 
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-continued 
—N \N / and 
H 
N 
S 
O// \\O 
and 
Where R2: 
O O 
0 
Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n:2-4; The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. 
betWeen about 0.0 and about 50 Weight percent of an addi 
tional antioxidant; 
betWeen about 0.0 and about 20 Weight percent of a Water 
soluble metal chelator; 
betWeen about 0.0 and about 50 Weight percent of glu 
tathione; 
betWeen about 0.0 and about 50 Weight percent of an addi 
tional dietary supplement that supports glutathione synthesis; 
and 
betWeen about 0.5 and about 50 Weight percent of a phar 
maceutically acceptable excipient. 
In the following description there is shoWn and described 
several different embodiments of the invention, simply by 
Way of illustration of some of the modes best suited to carry 
out the invention. As it Will be realiZed, the invention is 
capable of other different embodiments and its several details 
are capable of modi?cation in various, obvious aspects all 
Without departing from the invention. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS OF THE INVENTION 
The present invention relates to various methods of supple 
menting the diet of a mammal, removing heavy metals and 
other toxins from a mammal and relieving or ameliorating 
oxidative stress in a mammal. Each of the methods relies upon 
administering to said mammal a pharmaceutically effective 
amount of a compound having a chemical formula: 
US 8,426,368 B2 
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-continued 
and 
and 
Where R2: 
0 
0 
Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n:2 -4. The R4 attachment, other 
than hydrogen, converts the hydrophobic base compound to a 
hydrophilic, Water soluble compound. The R3 attachment 
makes the base compound susceptible to esterase conversion 
intracellular into a hydrophilic compound. The active com 
pounds and their synthesis are described in detail in copend 
ing U.S. patent application Ser. No. 12/731,415 ?led Mar. 25, 
2010, the full disclosure of Which is incorporated herein by 
reference. 
The pharmaceutically effective amount of the compounds 
in question may be administered in any appropriate manner 
including, but not limited to, oral administration, transdermal 
administration, nasal administration, intravenous admini stra 
tion and administration by suppository. The method of 
supplementing a diet of a mammal includes administering 
betWeen about 0.5 and about 40.0 mg of the compound per 
kilogram of the mammal’s total body Weight per day 
although, due to the lack of toxicity higher dose levels are 
acceptable. The compound may be administered in combina 
tion With another antioxidant or chelator. That antioxidant 
may be selected from a group including but not limited to 
vitamin-E, vitamin-D, cysteine, cystine, glutathione, lipoic 
acid and combinations thereof. 
US 8,426,368 B2 
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In the method of removing heavy metals and other toxins 
from a mammal, the compound is administered in an amount 
betWeen about 0.5 and about 60.0 mg per kilogram of the 
mammal’s total body Weight per day. In this method the 
compound may be administered With a Water soluble metal 
chelator. That Water soluble metal chelator may be selected 
from a group consisting of glutathione (GSH), dihydrolipoic 
acid (DLPA), lipoic acid (LPA), N-acetylcysteine (NAC), 
dimercaptopropane sulfonate (DMPS), dimercaptosuccinic 
acid (DMSA), ethylenediaminetetraacetic acid (EDTA), and 
mixtures thereof. It should be appreciated, hoWever, that other 
Water soluble metal chelators besides those listed could be 
utilized. 
In the method of relieving oxidative stress in a mammal the 
compound may be administered orally, transderrnally, 
nasally, intravenously, injected subcutaneously, by supposi 
tory and other appropriate methods. Typically the compound 
is administered in an amount of betWeen about 0.5 and about 
100.0 mg of the compound per kilogram of the mammal’s 
total body Weight per day. The exceptionally loW level of 
mammalian toxicity Would also alloW higher doses to be used 
in cases of acute toxicity or high oxidative stress. Here, it 
should also be noted that the present method may be used to 
treat oxidative stress resulting from virtually any cause or 
source including, but not limited to, heavy metal toxicity, 
drugs such as acetaminophen, xenobiotics, aging, infection, 
physical injury and disease. 
These compounds are not used to directly produce intrac 
ellular glutathione and Work primarily by salvaging naturally 
produced reduced glutathione (GSH) by the process of scav 
enging the intracellular ROSs preventing the oxidation to 
oxidized glutathione (GSSG). Also, the inhibitory binding of 
Hg2+ and Pb2+ and their removal from enzyme involved in the 
synthesis (e.g. glutatmine synthetase) and recovery of GSH 
(e.g. glutathione reductase) Would additionally aid in the 
recovery of GSH to optimal levels. In accordance With an 
additional aspect of the present invention the compound may 
be administered With a precursor of glutathione. That glu 
tathione precursor may be selected from a group of precursors 
consisting of cysteine, N-acetylcysteine, glycine, glutamate 
and combinations thereof. Also, removal of heavy metals 
from the iron-sulfur centers and other elements of the mito 
chondrial electron transport system Would dramatically 
reduce the mitochondrial production of hydroxyl free radi 
cals. It is Well knoWn that heavy metals make the mitochon 
dria into hydroxyl free radical producing species Where one 
heavy metal atom can cause the production of orders of mag 
nitude higher levels of hydroxyl free radicals. 
In yet another possible embodiment the compound is 
administered With a dietary supplement that supports glu 
tathione synthesis. Such dietary supplements include, but are 
not limited to, Whey protein, N-acetylcysteine, cysteine, glu 
tathione, nicotine adenine dinucleotide (NAD+), reduced 
nicotine adenine dinucleotide (NADH), glycylcysteine (gly 
cyc), glutamylcysteine (glu-cys), and combinations thereof. 
The compounds used in the present invention provide a 
number of unique bene?ts that make them attractive for use in 
methods of (a) supplementing the diet, (b) removing heavy 
metals and other toxins and (c) ameliorating oxidative stress 
in mammals. Many of the compounds exhibit very loW if any 
toxicity and do not adversely affect commonly used blood/ 
urine tests commonly used to measure human health. This 
loW toxicity is attributed to the fact that the aromatic rings are 
attached to the sulfhydryl containing chains via an amide 
connection that contains a carboxylate attached to the aro 
matic system. Any cleavage of this bond Would produce an 
aromatic carboxylate. Benzocarboxylate (e.g. monosodium 
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benzoate, a food preservative) and many other benzoates, and 
other more complex carboxylated aromatic ring systems, are 
not usually toxic due to their hydrophilic nature and ease of 
excretion. 
Advantageously the base compounds With hydrogen at R4, 
are lipid soluble and, accordingly, after entering the plasma 
can enter cells of all tissues, cross the blood brain barrier and 
enter the bone marroW. This is important because the damage 
caused by heavy metals and the oxidative stress produced by 
hydroxyl free radicals and other free radicals of the reactive 
oxygen species mostly occur in the intracellular space. In 
contrast, most dietary antioxidants are Water soluble and can 
not enter into cells effectively nor can they cross the blood/ 
brain barrier. As a further advantage, the lipid solubility of the 
compounds increases the time they spend in the body alloW 
ing them to be more effective at chelating heavy metals and 
scavenging hydroxyl free radicals. Chemical attachment of 
charged, natural compounds through the disul?de linkage 
produces Water soluble analogs (for intravenous application) 
of the base compounds Which Would be rapidly reduced in the 
blood back to the original hydrophobic compounds and alloW 
cell membrane permeation. Additionally, compounds con 
taining the methylester and ethylester linkages offer the 
advantage of being made into charged Water soluble species 
by enzymatic action of the natural esterases found in the 
mammalian body. This compound form starts out hydropho 
bic, can penetrate cell membranes after Which it is convertible 
to the charged Water soluble species by intracellular esterase 
activity, Which may have advantages for excretion through the 
kidneys. 
The compounds do not detectably disrupt any biochemical 
process in a mammal. They simply partition into the hydro 
phobic areas, bind heavy metals, react With free radicals 
eliminating them and are then excreted from the body prima 
rily through the biliary transport system of the liver. The 
pharmaceutical compositions of the present invention are 
characterized by having relatively high ORAC (Oxygen 
Radical-Absorbance-Capacity) scores. The ORAC score is 
measured by a compound or composition’s ability to enter 
separate reactive oxygen species or free radicals and prevent 
them from oxidizing a Water soluble ?uorescent vitamin-E 
derivative. The pharmaceutical compositions of the present 
invention have the ability in the body to protect vitamin E (a 
fat soluble vitamin) and other fat soluble natural compounds 
such as lipids from damage by oxidizing free radicals since 
the compositions partition into the hydrophobic areas Where 
they exist and react With free radicals more effectively 
thereby scavenging the hydroxyl free radicals and preventing 
them from doing damage. Signi?cantly, vitamin-E has been 
recommended for Alzheimers diseased subjects to prevent 
oxidizing damage to their brain membranes or membrane 
lipids due to vitamin’s E reactivity With hydroxyl free radi 
cals. The pharmaceutical compositions of the present inven 
tion are more capable of reacting With these radicals than 
vitamin E and, accordingly, the pharmaceutical compositions 
should provide even better protection. Mass Spectrometry 
evaluations of some of the compounds after incubation With 
human and rat liver homogenates have shoWn that the major 
products produced Were those With tWo and three oxygen 
atoms attached to the terminal sulfhydryl groups. This Would 
convert the sulfhydryl (iSH) to higher oxidized levels such 
as sul?tes (iSO3_) Which are charged and eliminated 
through the kidneys. 
The pharmaceutical compositions of the present invention 
are also characterized by an ability to increase the reduced 
(GSH) over oxidized (GSSG) glutathione ratio as Well as to 
increase the total glutathione in the Whole blood. Thus, more 
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glutathione is available to scavenge free radicals and partici- -Continued 
pate in the p-450 system to remove insoluble organic toxins 
from the membranes and cells. Thus, the body is better able to 
maintain a healthy glutathione level When the diet of the 
mammal is supplemented With compositions of the present 5 
invention. 
Further, the pharmaceutical compositions of the present 
invention are characterized by good stability When stored. 
They also generally exhibit a very loW odor level thereby 10 
making them more palatable for oral administration. 
Generally, the pharmaceutical compositions of the present 
invention are better than glutathione delivered by IV or trans 
dermally for increasing the intracellular level of glutathione. 
The rationale behind this is based on the very loW level of 15 
glutathione found in the plasma versus the intercellular levels 
Which are one thousand to ten thousand times higher. Any 
glutathione molecule that enters the blood by IV or transder 
mal delivery is immediately bound and removed by the glu 
tathione receptors in the liver that are used to take glutathione 
labeled toxins and viruses out of the plasma and place them in 
the bile (biliary transport system). Glutathione in the blood 
Would not remain long enough to enter cells Where it could be 
used, plus do to its highly charged character (2 negative and 1 
positive charges/molecule) GSH Would have to enter via spe 
ci?c carriers in the face of a signi?cant concentration gradient 
that Would prevent this. This statement is based on the fact 
that many Water insoluble toxicants are removed from the 
body by ?rst oxidiZing them, attaching glutathione (by the 30 
enZyme glutathione-s-transferase) to this oxidiZed site on the 
toxin, then actively transporting the glutathione labeled toxi 
cant out of the cell and into the blood Where it is actively 
removed by the glutathione receptors of the biliary transport 
system. In contrast, pharmaceutical compositions of the 35 
present invention face no concentration gradients and can 
enter all cells and due to their hydrophobic nature, insert to 
some degree into the lipid membrane or other hydrophobic 
sites Where they can scavenge hydroxyl free radicals, the 
major chemical species that oxidiZe glutathione and cause its 
levels to drop. The pharmaceutical compositions salvage 
naturally produced glutathione intracellular enhancing its 
longevity and raising glutathione levels in-vivo Without hav 
ing to battle transport across a membrane against a high 
gradient of glutathione. 
25 
45 
Pharmaceutical compositions of the present invention may 
be prepared by combining a pharmaceutically effective I 
amount of a compound having a chemical formula: , , N 
50 CH3 
55 
I 60 E? 
\N s 
(ll 
Where R1: 
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-continued 
H 
N 
Where R3 :ethyl or methyl, R4:hydrogen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphosphate, 
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap 
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro 
acetate or chloroacetate and n 2-4, With an excipient. Sub 
stantially any suitable excipient may be utilized including but 
not limited to albumin, almond oil, ascorbic acid, benZoic 
acid, calcium stearate, canola oil, calcium carboxymethylcel 
lulose, sodium carboxymethylcellulose, castor oil, hydroge 
nated castor oil, microcrystalline cellulose, corn oil, cotton 
seed oil, cyclodextrins, ethylene glycol palmitostearate, gela 
tin, glycerin, hydroxyethyl cellulose, hydroxyethylmethyl 
cellulose, hydroxypropyl cellulose, hypermellose, loW-sub 
stituted hydroxypropyl cellulose, lanolin, linoleic acid, mag 
nesium silicate, magnesium stearate, medium-chain triglyc 
erides, mineral oil, olive oil, peanut oil, pectin, compressible 
sugar, sun?ower oil, hydrogenated vegetable oil, Water and 
combinations thereof. In order to provide multiple antioxi 
dant potential, the pharmaceutical compositions may further 
include other antioxidants including, but not limited to vita 
min-E, vitamin-D, cystine, glutathione, lipoic acid and com 
binations thereof. Further the pharmaceutical compositions 
may include a Water soluble metal chelator to enhance 
removal of toxic metals both through the liver and kidney and 
With an enhanced rate. Substantially, any suitable Water 
soluble metal chelator may be utiliZed including but not lim 
ited to glutathione (GSH), dihydrolipoic acid (DLPA), lipoic 
acid (LPA), N-acetylcysteine (NAC), dimercaptopropane sul 
fonate (DMPS), dimercaptosuccinic acid (DMSA), ethylene 
diaminetetraacetic acid (EDTA), and mixtures thereof. Fur 
ther, in order to further enhance the levels of glutathione in the 
subject, the pharmaceutical compositions may include a pre 
cursor of glutathione Which may be selected from a group 
including but not limited to cysteine, glycine, glutamate and 
combinations thereof. Further pharmaceutical compositions 
may include a dietary supplement that supports glutathione 
synthesis. Substantially any appropriate dietary supplement 
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that supports glutathione synthesis may be utiliZed including 
but not limited to Whey protein, N-acetylcystein, cysteine, 
glutathione, nicotine adenine dinucleotide (NAD+), reduced 
nicotine adenine dinucleotide (NADH), glycylcysteine (gly 
cys), glutamylcysteine (glu-cyc), and combinations thereof. 
Pharmaceutical compositions may also include various bind 
ers, preservatives, mineral supplements, bulking agents, dilu 
ents, carriers, ?avoring agents that are Widely knoWn to be 
used in pharmaceutical compositions. Exemplary pharma 
ceutical compositions include betWeen about 95.5 and about 
85 Weight percent active compound, betWeen about 0.5 and 
about 15 Weight percent excipient. The optional additional 
antioxidant(s) may be provided at betWeen about 0 and about 
50 Weight percent. The optional additional Water soluble 
metal chelator may be provided at betWeen about 0 and about 
20 Weight percent. The optional additional precursor of glu 
tathione may be provided at betWeen about 0 and about 50 
Weight percent. Further the optionally additional dietary 
supplement that supports glutathione synthesis may be pro 
vided at betWeen about 0 and about 50 Weight percent. One or 
more of any of the optional additives may be included. The 
optional additive replaces a like percentage of the compound 
in the ?nal composition. 
Preferred dosage forms for oral administration include the 
isolated compounds in poWder form. Such poWders may be 
taken up With a scoup and spread onto food or mixed into 
drinks for easy consumption Without bad taste. The pure 
compounds may be pre-mixed With certain dietary ingredi 
ents such as butter, olive oil, corn oil, albumin, Whey or other 
foods Which Will help in absorption of the compounds by the 
mere process of dissolving them. It has been determined that 
it takes about tWo hours post ingestion for the maximum level 
of active ingredient to shoW up in the plasma of all tested 
animals. Further, after 24 hours post-ingestion the active 
ingredient levels Were shoWn to drop between 4-12% of the 
peak values seen at hour 2. 
Some of the commercially available solubiliZers that can 
be used for parenteral (inj ectible), oral, topical or intranasal 
delivery in different combinations and ratios according to 
need include: (a) co-solvents such as polyethylene glycol 
300/400, Macrogol 300/400, Lutrol E300/E400, propylene 
glycol, Soluphor P and NMP; (b) PEG derivatives such as 
Cremophor RH40, Cremophor EL/ELP and Solutol HS-l5; 
and (c) polyoxamers such as Lutrol F68, Lutrol F127, Lutrol 
Micro 68 and Lutrol Micro 127. 
The pure compound may be encapsulated in several Weight 
forms (eg. 50, 100, 200, 500 mg/capsule) and taken orally. 
The pure compound may be mixed With excipients (eg. 
microcrystalline cellulose, hyper'mellose, magnesium stear 
ate) to provide a mixed material that can be ef?ciently encap 
sulated by machines for mass production at a rapid rate. 
The pure compound may also be made into tablet form by 
mixing With common agents or binders used to induce adhe 
sive properties for tablet formation. 
Any of the other hydrophobic compounds may be dis 
solved in simple oils and applied to the skin. The compounds 
dissolved in DMSO (dimethylsulfoxide) are rapidly taken up 
through the skin Without local irritation. Also, dissolving the 
compounds in Warm butter alloWs them to be applied trans 
dermally. 
The compounds may be placed in suppository capsules 
either in poWder form or dissolved in oils or as mixed With 
protein based material (eg. human serum albumin, HSA) for 
delivery. The compounds may also be dissolved in human 
serum albumin for intravenous delivery. Similarly, blood 
could be pulled from a patient and the compounds added to 
that blood before being returned to the patient. This property 
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is allowed as HSA is a Water soluble protein With hydropho 
bic areas designed to carry natural hydrophobic molecules 
through the blood to cells Where they are transferred to cell 
membranes. 
The compositions and methods of the present invention 
may be accomplished by various means Which are illustrated 
in the examples beloW. These examples are intended to be 
illustrative only as numerous modi?cations and variations 
Will be apparent to those skilled in the art. 
EXAMPLE 1 
Compounds have been produced and used by test animals 
and humans in pure poWder form in resealable plastic bags 
accompanied With a pharmaceutical spoon that alloWs deliv 
ery of compound at 50 to 100 mg/ spoonful. The pure poWder 
can be taken directly into the oral cavity for sublingual deliv 
ery or mixed With foods and drinks. The mixing of these 
compounds has been done With oily foods such as butter, olive 
oil, peanut butter to enhance their solubiliZation prior to 
ingestion and uptake in the digestive tract. 
EXAMPLE 2 
Compounds have been mixed With excipients magnesium 
stearate, microcrystalline cellulose, hypermellose and silicon 
dioxide to form a pharmaceutical composition administered 
in capsules of 50, 100 and 200 mg quantities of compound for 
oral ingestion by humans. 
EXAMPLE 3 
Compounds have been dissolved in natural oils such as 
olive oil, cod liver oil, corn oil, butter and taken orally by 
humans. 
EXAMPLE 4 
Compounds have been dissolved in natural oils such as 
olive oil, cod liver oil, corn oil, butter and applied to the skin 
With rubbing to affect a transdermal delivery of the compound 
into humans. 
EXAMPLE 5 
Compounds have been dissolved in DMSO (dimethylsul 
foxide):isotonic sodium chloride (25%:75% mixtures) and 
injected subcutaneously into test animals With excellent 
results. 
EXAMPLE 6 
Compounds have been dissolved in Solutol HS 15 and 
NMP mixtures for both subcutaneous and intravenous deliv 
ery into test animals as folloWs: 
1. Prepare 1:1 W/v of NMP and Solutol HS 15 
2. Weigh out the required amount of the pharmaceutically 
effective compound in poWder form. 
3. Add required amount of the 1:1 mixture. (20% of ?nal 
volume) 
4. Vortex to make sure that the compound is in solution. 
5. SloWly add the Normal saline (80% of ?nal volume) 
6. Sonicate for a feW minutes to get a clear solution. 
EXAMPLE 7 
Pharmaceutically effective compounds of the invention 
have been dissolved in Cremophor and ethyl alcohol mixtures 
for both subcutaneous and intravenous delivery into test ani 
mals as folloWs: 
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1. Prepare a 1:1 W/v of ethyl alcohol and Cremophor. 
2. Weigh out the required amount of OSR#1 poWder. 
3. Add the required amount to the 1:1 mixture. 
4. Vortex to make sure OSR is in solution. 
5. Sonicate if necessary for a feW minutes. 
6. SloWly add Normal Saline 50 to 80% of the ?nal volume. 
EXAMPLE 8 
A dosing solution for intravenous administration (IV) into 
test animals Was prepared at 1 mg/mL in a formulation con 
sisting of 80% normal saline (NS) and 20% of a 1:1 mixture 
of N-methylpyrrolidone (N MP) and Solutol HS15. This Was 
used successfully to determine the plasma half life of one of 
the compounds in mice. 
EXAMPLE 9 
Medicament and/ or preparation of dosage form. To prepare 
a medicament and/or suitable dosage form, the pharmaceuti 
cally active compound of the invention may be admixed and/ 
or contacted With one or more of the excipients listed in Table 
9-1 . 
TABLE 9-1 
Excipi ents 
Acacia 
Acesulfame Potassium 
Acetic Acid, Glacial 
Acetone 
Acetyltributyl Citrate 
Acetyltriethyl Citrate 
Agar 
Albumin 
Alcohol 
Alginic Acid 
Aliphatic Polyesters 
Alitame 
Almond Oil 
Alpha Tocopherol 
Aluminum Hydroxide Adjuvant 
Aluminum Oxide 
Aluminum Phosphate Adjuvant 
Aluminum Stearate 
Ammonia Solution 
Ammonium Al ginate 
Ascorbic Acid 
Ascorbyl Palmitate 
Aspartame 
Attapulgite 
Bentonite 
Benzalkonium Chloride 
Benzethonium Chloride 
Benzoic Acid 
Benzyl Alcohol 
Benzyl Benzoate 
Boric Acid 
Bronopol 
Butylated Hydroxyanisole 
Butylated Hydroxytoluene 
Butylparaben 
Calcium Al ginate 
Calcium Carbonate 
Calcium Phosphate, Dibasic Anhydrous 
Calcium Phosphate, Dibasic Dihydrate 
Calcium Phosphate, Tribasic 
Calcium Stearate 
Calcium Sulfate 
Canola Oil 
Carbomer 
Carbon Dioxide 
Carboxymethylcellulose Calcium 
Carboxymethylcellulose Sodium 
Carrageenan 
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TABLE 9- 1 -continued TABLE 9-1 -c0ntinued 
Excipients Excipients 
Castor Oil Hydroxypropyl Cellulose, LoW-substituted 
Castor Oil, Hydrogenated 5 Hydroxypropyl Starch 
Cellulose, Microcrystalline Hyprornellose 
Cellulose, Powdered Hyprornellose Acetate Succinate 
Cellulose, Silici?ed Microcrystalline Hyprornellose Phthalate 
Cellulose Acetate Irnidurea 
Cellulose Acetate Phthalate Inulin 
Ceratonia 10 Iron Oxides 
Cetostearyl Alcohol Isornalt 
Cetrirnide Isopropyl Alcohol 
Cetyl Alcohol Isopropyl Myristate 
CetylpyridiniuIn Chloride Isopropyl Palrnitate 
Chitosan Kaolin 
Chlorhexidine 1 5 Lactic Acid 
Chlorobutanol Lactitol 
Chlorocresol Lactose, Anhydrous 
Chlorodi?uoroethane (HCFC) Lactose, Monohydrate 
Chlorofluorocarbons (CFC) Lactose, Spray-Dried 
Chloroxylenol Lanolin 
Cholesterol Lanolin, Hydrous 
Citric Acid Monohydrate 20 Lanolin Alcohols 
Colloidal Silicon Dioxide Lauric Acid 
Coloring Agents Lecithin 
Copovidone Leucine 
Corn Oil Linoleic Acid 
Cottonseed Oil Macrogol 15 Hydroxystearate 
Cresol 25 MagnesiuIn AlUIHlHUIH Silicate 
Croscarrnellose Sodiurn MagnesiuIn Carbonate 
Crospovidone MagnesiuIn Oxide 
Cyclodextrins MagnesiuIn Silicate 
Cyclornethicone MagnesiuIn Stearate 
Denatoniurn BenZoate MagnesiuIn Trisilicate 
Dextrates 30 Malic Acid 
Dextrin Maltitol 
Dextrose Maltitol Solution 
Dibutyl Phthalate Maltodextrin 
Dibutyl Sebacate Maltol 
Diethanolalnine Maltose 
Diethyl Phthalate 3 5 Mannitol 
Difluoroethane (HFC) Mediurn-chain Triglycerides 
Dirnethicone MegluInine 
Dirnethyl Ether Menthol 
Dirnethyl Phthalate Methylcellulose 
Dirnethyl Sulfoxide Methylparaben 
Dirnethylacetalnide Mineral Oil 
Disodiurn Edetate 40 Mineral Oil, Light 
Docusate SodiuIn Mineral Oil and Lanolin Alcohols 
Edetic Acid Monoethanolalnine 
Erythorbic Acid MonosodiuIn Glutalnate 
Erythritol Monothioglycerol 
Ethyl Acetate Myristic Acid 
Ethyl Lactate 45 Neohesperidin Dihydrochalcone 
Ethyl Maltol Nitrogen 
Ethyl Oleate Nitrous Oxide 
Ethyl Vanillin Octyldodecanol 
Ethylcellulose Oleic Acid 
Ethylene Glycol Palrnitostearate Oleyl Alcohol 
Ethylene Vinyl Acetate 50 Olive Oil 
Ethylparaben Palrnitic Acid 
Fructose Paraf?n 
Furnaric Acid Peanut Oil 
Gelatin Pectin 
Glucose, Liquid Petrolaturn and Lanolin Alcohols 
Glycerin 5 5 Petrolaturn 
Glyceryl Behenate Phenol 
Glyceryl Monooleate Phenoxyethanol 
Glyceryl Monostearate Phenylethyl Alcohol 
Glyceryl Palrnitostearate Phenylrnercuric Acetate 
Glycofurol Phenylrnercuric Borate 
Guar Gurn Phenylrnercuric Nitrate 
Hectorite 60 Phosphoric Acid 
Hepta?uoropropane (HFC) Polacrilin Potassiurn 
Hexetidine PoloxaIner 
Hydrocarbons (HC) Polycarbophil 
Hydrochloric Acid Polydextrose 
Hydroxyethyl Cellulose Polyethylene Glycol 
65 Hydroxyethylrnethyl Cellulose 
Hydroxypropyl Cellulose 
Polyethylene Oxide 
Polyrnethacrylates 
2 5 
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TABLE 9-1 -continued 
Excip ients 
Poly(methyl vinyl ether/maleic anhydride) 
Polyoxyethylene Alkyl Ethers 
Polyoxyethylene Castor Oil Derivatives 
Polyoxyethylene Sorbitan Fatty Acid Esters 
Polyoxyethylene Stearates 
Polyvinyl Acetate Phthalate 
Polyvinyl Alcohol 
Potassium Alginate 
Potassium BenZoate 
Potassium Bicarbonate 
Potassium Chloride 
Potassium Citrate 
Potassium Hydroxide 
Potassium Metabisul?te 
Potassium Sorbate 
Povidone 
Propionic Acid 
Propyl Gallate 
Propylene Carbonate 
Propylene Glycol 
Propylene Glycol Alginate 
Propylparaben 
2-Pyrrolidone 
Saccharin 
Saccharin Sodium 
Saponite 
Sesame Oil 
Shellac 
Simethicone 
Sodium Acetate 
Sodium Alginate 
Sodium Ascorbate 
Sodium BenZoate 
Sodium Bicarbonate 
Sodium Borate 
Sodium Chloride 
Sodium Citrate Dihydrate 
Sodium Cyclamate 
Sodium Hyaluronate 
Sodium Hydroxide 
Sodium Lactate 
Sodium Lauryl Sulfate 
Sodium Metabisul?te 
Sodium Phosphate, Dibasic 
Sodium Phosphate, Monobasic 
Sodium Propionate 
Sodium Starch Glycolate 
Sodium Stearyl Fumarate 
Sodium Sul?te 
Sorbic Acid 
Sorbitan Esters (Sorbitan Fatty Acid Esters) 
Sorbitol 
Soybean Oil 
Starch 
Starch, PregelatiniZed 
Starch, SteriliZable Maize 
Stearic Acid 
Stearyl Alcohol 
Sucralose 
Sucrose 
Sugar, Compressible 
Sugar, Confectioner’s 
Sugar Spheres 
Sulfobutylether [5-Cyclodextrin 
Sul?aric Acid 
Suppository Bases, Hard Fat 
Talc 
Tartaric Acid 
Tetra?uoroethane (HFC) 
Thaumatin 
Thymol 
Titanium Dioxide 
Tragacanth 
Trehalose 
Triacetin 
Tributyl Citrate 
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Excipi ents 
Triethanolamine 
Triethyl Citrate 
Vanillin 
Vegetable Oil, Hydrogenated 
Water 
Wax, Anionic Emulsifying 
Wax, Carnauba 
Wax, Cetyl Esters 
Wax, Microcrystalline 
Wax, Nonionic Emulsifying 
Wax, White 
Wax, YelloW 
Xanthan Gum 
Xylitol 
Zein 
Zinc Acetate 
Zinc Stearate 
EXAMPLE 10 
Dosage form. A suitable dosage form for administration of 
the pharmaceutically active compound of the present inven 
tion may be chosen from among the dosage forms listed in 
Table 10-1. 
TABLE 10-1 
Dosage forms 
NAME DEFINITION 
AEROSOL A product that is packaged under pressure and 
contains therapeutically active ingredients that are 
released upon activation of an appropriate valve 
system; it is intended for topical application to the 
skin as Well as local application into the nose 
(nasal aerosols), mouth (lingual aerosols), or lungs 
(inhalation aerosols). 
A product that is packaged under pressure and 
contains therapeutically active ingredients, in the 
form of a poWder, that are released upon 
activation of an appropriate valve system. 
A solid dosage form usually in the form ofa 
rectangle that is meant to be cheWed. 
AEROSOL, 
POWDER 
BAR, CHEWABLE 
CAPSULE A solid oral dosage form consisting of a shell and 
a ?lling. The shell is composed ofa single sealed 
enclosure, or tWo halves that ?t together and 
Which are sometimes sealed With a band. Capsule 
shells may be made from gelatin, starch, or 
cellulose, or other suitable materials, may be soft 
or hard, and are ?lled With solid or liquid 
ingredients that can be poured or squeezed. 
CAPSULE, A solid dosage form in Which the drug is enclosed 
COATED Within either a hard or soft soluble container or 
“shell” made from a suitable form of gelatin; 
additionally, the capsule is covered in a designated 
coating. 
CAPSULE, A solid dosage form in Which the drug is enclosed 
COATED Within either a hard or soft soluble container or 
PELLETS “shell” made from a suitable form of gelatin; the 
drug itself is in the form ofgranules to Which 
varying amounts of coating have been applied. 
CAPSULE, A solid dosage form in Which the drug is enclosed 
COATED, Within either a hard or soft soluble container or 
EXTENDED “shell” made from a suitable form of gelatin; 
RELEASE additionally, the capsule is covered in a designated 
coating, and Which releases a drug (or drugs) in 
such a manner to alloW at least a reduction in 
dosing frequency as compared to that drug (or 
drugs) presented as a conventional dosage form. 
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TABLE 10-1-c0ntinued 
Dogge forms Dogge forms 
NAME DEFINITION 5 NAME DEFINITION 
CAPSULE, A solid dosage form in Which the drug is enclosed EXTRACT A concentrated preparation of vegetable or animal 
DELAYED Within either a hard or soft soluble container made drugs obtained by removal of the active 
RELEASE from a suitable form of gelatin, and Which releases constituents of the respective drugs With a suitable 
a drug (or drugs) at a time other than promptly menstrua, evaporation of all or nearly all of the 
after administration. Enteric-coated articles are solvent, and adjustment of the residual masses or 
delayed release dosage forms. 10 poWders to the prescribed standards. 
CAPSULE, A solid dosage form in Which the drug is enclosed FIBER, A slender and elongated solid thread-like 
DELAYED Within either a hard or soft soluble container or EXTENDED substance that delivers drug in such a manner to 
RELEASE “shell” made from a suitable form of gelatin; the RELEASE alloW a reduction in dosing frequency as 
PELLETS drug itself is in the form of granules to Which compared to that drug (or drugs) presented as a 
enteric coating has been applied, thus delaying conventional dosage form. 
release of the drug until its passage into the 15 FILM, SOLUBLE A thin layer or coating Which is susceptible to 
intestines. being dissolved When in contact With a liquid. 
CAPSULE, A solid dosage form in Which the drug is enclosed FOR SOLUTION A product, usually a solid, intended for solution 
EXTENDED Within either a hard or soft soluble container made prior to administration. 
RELEASE from a suitable form of gelatin, and Which releases FOR SUSPENSION A product, usually a solid, intended for suspension 
a drug (or drugs) in such a manner to alloW a prior to administration. 
reduction in dosing frequency as compared to that FOR A product, usually a solid, intended for suspension 
drug (or drugs) presented as a conventional dosage 20 SUSPENSION, prior to administration; once the suspension is 
form. EXTENDED administered, the drug Will be released at a 
CAPSULE, FILM A solid dosage form in Which the drug is enclosed RELEASE constant rate over a speci?ed period. 
COATED, Within either a hard or soft soluble container or GEL A semisolid3 dosage form that contains a gelling 
EXTENDED “shell” made from a suitable form of gelatin; agent to provide stiffness to a solution or a 
RELEASE additionally, the capsule is covered in a designated colloidal dispersion.4 A gel may contain 
?lm coating, and Which releases a drug (or drugs) 25 suspended particles. 
in such a manner to alloW at least a reduction in GLOBULE Also called pellets or pilules, are made of pure 
dosing frequency as compared to that drug (or sucrose, lactose, or other polysaccharides. They 
drugs) presented as a conventional dosage form. are formed into small globular masses of various 
CAPSULE, A solid dosage form in Which the drug is enclosed sizes, and are medicated by placing them in a vial 
GELATIN Within either a hard or soft soluble container made and adding the liquid drug attenuation in the 
COATED from a suitable form of gelatin; through a banding 30 proportion not less than one percent (v/W). After 
process, the capsule is coated With additional shaking, the medicated globules are dried at 
layers of gelatin so as to form a complete seal. temperatures not to exceed 40 degrees Centigrade. 
CAPSULE, A solid dosage form in Which the drug is enclosed GRANULE A small particle or grain. 
LIQUID Within a soluble, gelatin shell Which is plasticiZed GRANULE, A small medicinal particle or grain to Which an 
FILLED by the addition of a polyol, such as sorbitol or DELAYED enteric or other coating has been applied, thus 
glycerin, and is therefore of a someWhat thicker 35 RELEASE delaying release of the drug until its passage into 
consistency than that of a hard shell capsule; the intestines. 
typically, the active ingredients are dissolved or GRANULE, A small particle or grain containing a medicinal 
suspended in a liquid vehicle. EFFERVESCENT agent in a dry mixture usually composed of 
CONCENTRATE A liquid preparation of increased strength and sodium bicarbonate, citric acid, and tartaric acid 
reduced volume Which is usually diluted prior to Which, When in contact With Water, has the 
administration. capability to release gas, resulting in 
CORE, An ocular system placed in the eye from Which the 40 effervescence. 
EXTENDED drug diffuses through a membrane at a constant GRANULE, FOR A small medicinal particle or grain made available 
RELEASE rate over a speci?ed period. SOLUTION in its more stable dry form, to be reconstituted 
CREAM An emulsion, semisolid3 dosage form, usually With solvent just before dispensing; the granules 
containing >20% Water and volatiles5 and/or <50% are so prepared to contain not only the medicinal 
hydrocarbons, Waxes, or polyols as the agent, but the colorants, ?avorants, and any other 
vehicle. This dosage form is generally for 45 desired pharmaceutic ingredient. 
external application to the skin or mucous GRANULE, FOR A small medicinal particle or grain made available 
membranes. SUSPENSION in its more stable dry form, to be reconstituted 
CREAM, A cream dosage form that enhances drug delivery. With solvent just before dispensing to form a 
AUGMENTED Augmentation does not refer to the strength of the suspension; the granules are so prepared to contain 
drug in the dosage form. NOTE: CDER has not only the medicinal agent, but the colorants, 
decided to refrain from expanding the use of this 50 ?avorants, and any other desired pharmaceutic 
dosage form due to dif?culties in setting speci?c ingredient. 
criteria that must be met to be considered GRANULE, FOR A small medicinal particle or grain made available 
“augm@nt@d”_ SUSPENSION, in its more stable dry form, to be reconstituted 
DRUG DELIVERY Modern technology, distributed With or as a part EXTENDED With Solvent lust b?fom disp?nsing to £01m a 
SYSTEM of a ding product that allows for the uniform RELEASE suspension; the extended release system achieves 
ml?as? or targeting of drugs to th6 body 55 sloW release ofthe ‘drug over an extended period 
ELIXIR A 016m, pl?asantly ?avomd, swwten?d oftime and maintains constant drug levels in the 
hydroalcoholic liquid containing dissolved blood or targ?t US$116‘ 
. . . . . INJECTABLE, An injection, Which either consists of or forms 
medicinal agents; it is intended for oral use. . . . . . 
. . LIPOSOMAL liposomes (a lipid bilayer vesicle usually 
EMULSION A dosage form consisting ofa tWo-phase system . . . . 
, , , , , , l composed ofphospholipids Which is used to 
comprised of at least tWo immiscible liquids , one ?ncapsulat? an activ? drug Substanc6>_ 
ofwhlch 1S dlspersfd as droplfts (mtfmal or 60 INJECTION A sterile preparation intended for parenteral use; 
disp?rs?d P115156) Within the other liquid (External ?ve distinct classes of injections exist as de?ned 
or continuous phase), generally stabilized With one by the USP_ 
or mom 6nullsifying agents- (Nomi Emulsion is INJECTION, An emulsion consisting of a sterile, pyrogen-free 
used as a dosage form term unless a more speci?c EMULSION preparation intended to be administered 
term is applicable, e. g. cream, lotion, ointment.) parenterally. 
ENEMA A rectal preparation for therapeutic, diagnostic, or 65 INJECTION, LIPID [de?nition pending] 
nutritive purposes. COMPLEX 
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TABLE 10-1-c0ntinued 
Dogge forms Dogge forms 
NAME DEFINITION 5 NAME DEFINITION 
INJECTION, A sterile preparation intended for reconstitution to OINTMENT, An ointment dosage form that enhances drug 
POWDER, form a solution for parenteral use. AUGMENTED delivery. Augmentation does not refer to the 
FOR SOLUTION strength of the drug in the dosage form. NOTE: 
INJECTION, A sterile preparation intended for reconstitution to CDER has decided to refrain from expanding the 
POWDER, form a suspension for parenteral use. use of this dosage form due to dil?culties in 
FOR SUSPENSION 10 setting speci?c criteria that must be met to be 
INJECTION, A dried preparation intended for reconstitution to considered “augmented”. 
POWDER, form a suspension for parenteral use Which has PASTE A semisolid3 dosage form, containing a large 
FOR proportion (20-50%) ofsolids ?nely dispersed in 
SUSPENSION, been formulated in a manner to alloW at least a a fatty vehicle. This dosage form is generally for 
EXTENDED reduction in dosing frequency as compared to that external application to the skin or mucous 
RELEASE drug presented as a conventional dosage form 15 membranes. 
(e.g., as a solution). PASTILLE An aromatic preparation, often With a pleasing 
INJECTION, A sterile freeze dried preparation intended for flavor, usually intended to dissolve in the mouth. 
POWDER, reconstitution for parenteral use Which has been PATCH A drug delivery system that often contains an 
LYOPHILIZED, formulated in a manner that Would alloW adhesive backing that is usually applied to an 
FOR liposomes (a lipid bilayer vesicle usually external site on the body. Its ingredients either 
LIPOSOMAL composed of phospholipids Which is used to passively diffuse from, or are actively transported 
SUSPENSION encapsulate an active drug substance, either Within 20 from, some portion of the patch. Depending upon 
a lipid bilayer or in an aqueous space) to be the patch, the ingredients are either delivered to 
formed upon reconstitution. the outer surface of the body or into the body. A 
INJECTION, A liquid preparation, suitable for injection, Which patch is sometimes synonymous With the terms 
SUSPENSION, consists of an oil phase dispersed throughout an ‘extended release ?lm’ and ‘system’. 
LIPOSOMAL aqueous phase in such a manner that liposomes (a PATCH, A drug delivery system in the form of a patch that 
lipid bilay?r Vesicl? usually Composed of 25 EXTENDED releases the drug in such a manner that a reduction 
Phospholipids Which is used to 61103131113“? an RELEASE in dosing frequency compared to that drug 
actIiW d-mg Substanc6> Fith?r Within a lipid bilay?r presented as a conventional dosage form (e.g., a 
or 1In aqu?ous Ispac?) Iare fonn?Id'I I I solution or a prompt drug-releasing, conventional 
INJECTION, A liquid preparation, suitable for IHJECUOH, Which Solid dosag? form)_ 
SUSPENSION, consists of solid particles dispersed throughout a PATCH, A drug deliv?ry syst?m in th? form ofa patch 
SONICATED liquid phase in Which the particles are not soluble. 30 . . . 
. . . . . . EXTENDED Which is controlled by an electric current that 
In addition, the product is sonicated While a gas is . . 
bubbled through th? susp?nsion, and this msults in RELEASE, releases the drug in such a manner that a reduction 
th? formation ofmicrosph?ms by th? Solid ELECTRICALLY in dosing frequency compared to that drug 
pmicl6S_ CONTROLLED presented as a conventional dosage form (e.g., a 
JELLY A class of gels, Which are semisolid systems that Solution or a prompt drug'mleasing> conv?ntional 
consist of suspensions made up of either small 35 Solid dosag6 form) 
inorganic pa?icles or large Organic molecules PELLET A small sterile solid mass consisting ofa highly 
interpenetrated by a liquidiin Which the structural puri?ed drug (With or Without excipients) made by 
coherent matrix contains a high portion of liquid, the formation of granules, or by compression and 
usually Water. molding. 
KIT A Packag?d Collection Ofr?lat?d In?tefi?l- PELLETS, A solid dosage form in Which the drug itself is in 
LINIMENT A solution or mixture of various substances in oil, 40 COATEDI the form of granules to Which varying amounts of 
alcoholic solutiops OIfSOaP, or emulsions intend?d EXTENDED coating have been applied, and Which releases a 
for I?xtfimal applIlcatlon' I RELEASE drug (or drugs) in such a manner to alloW a 
LIQUID’ A hquld that déhvérs a dfmg m Such a mann?r to reduction in dosing frequency as compared to that 
EXTENDED alloW a reduction in dosing frequency as ding (or dings) pmsent?d as a conventional dosag? 
RELEASE compared to that drug (or drugs) presented as a form 
conventional dosage form. ' . . . 
LOTION An emulsion, liquidl dosage form. This dosage 45 PILL A snlmln’ round slohd dosag? form contlallmng Ia 
form is g?n?any for ?xt?mal application to th? medicinal agent intended for oral administration. 
Skin} PLASTER Substance intended for external application made 
LOTION, A lotion dosage form that enhances drug delivery. of Such mammals and Ofsuch Consistency as to 
AUGMENTED Augmentation does not refer to the strength of the ad-h?re to the Skin and attach to a dressing; Plast?rs 
drug in the dosage fOImI NOTE; CDER has are intended to afford protection and support 
decided to refrain from expanding the use of this 50 and/or to furnish an occlusion and macerating 
dosage form due to dif?culties in setting speci?c action and to bring medication into close contact 
criteria that must be met to be considered With the skin. 
“augm?nt?w- POULTICE A soft, moist mass ofmeal, herbs, seed, etc., 
LOZENGE A solid preparation containing one or more usually applied hot in cloth that consists of gmep 
medicaments, usually in a flavored, sWeetened Mk6 consist?ncy 
base Which is intended to dissolve or disintegrate 55 POWDER An intimat? mixmm ofdry, ?nd}, divid?d dings 
:iflly m the mouth‘ A lollipop 1S a lounge on 5 and/or chemicals that may be intended for internal 
' , , , or external use. 
MOUTHWASH aqueous solution Which is most often used for POWDER, FOR An intimat? mixmm of dry, ?ndy divid?d dings 
its deodorant, refreshing, or antiseptic effect. . . . . 
OIL An uncmous, Combustible Substanc? which is SOLUTION and/or chemicals, Which, upon the addition of 
liquid, or easily lique?able, on Warming, and is Suitable v?hlclés’ ywlds a Solution‘ I I 
Solubl? in ‘Ether but insolubl? in Watm Such 60 POWDER, FOR An intimate mixture ofdry, ?nely divided drugs 
Substanws, dep?nding on than Origin, am SUSPENSION and/or chemicals, Which, upon the addition of 
classi?ed as animal, mineral, or vegetable oils. Suitable V?hicles, yi?lds a Susp?nsion (3 liquid 
OINTMENT A semisolid3 dosage form, usually containing preparation Containing the Solid Pmieles dispersal 
<20% Water and volatiles5 and >50% in the liquid vehicle). 
hydrocarbons, Waxes, or polyols as the vehicle. SALVE A thick ointment or cerate (a fat or Wax based 
65 This dosage form is generally for external 
application to the skin or mucous membranes. 
preparation With a consistency betWeen an 
ointment and a plaster). 
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TABLE 10-1-continued 
Dogge forms Dogge forms 
NAME DEFINITION 5 NAME DEFINITION 
SOLUTION A clear, homogeneous liquidl dosage form that TABLET, A solid dosage form containing mixtures of acids 
contains one or more chemical substances EFFERVESCENT (e. g., citric acid, tartaric acid) and sodium 
dissolved in a solvent or mixture of mutually bicarbonate, Which release carbon dioxide When 
miscible solvents. dissolved in Water; it is intended to be dissolved or 
SOLUTION, A liquid preparation (i.e., a substance that floWs dispersed in Water before administration. 
CONCENTRATE readily in its natural state) that contains a drug 10 TABLET, A solid dosage form containing a drug Which 
dissolved in a suitable solvent or mixture of EXTENDED alloWs at least a reduction in dosing frequency as 
mutually miscible solvents; the drug has been RELEASE compared to that drug presented in conventional 
strengthened by the evaporation of its nonactive dosage form. 
parts. TABLET, FILM A solid dosage form that contains medicinal 
SOLUTION, FOR A solution for the preparation of an iced saline COATED substances With or Without suitable diluents and is 
SLUSH slush, Which is administered by irrigation and used 15 coated With a thin layer of a Water-insoluble or 
to induce regional hypothermia (in conditions Water-soluble polymer. 
such as certain open heart and kidney surgical TABLET, FILM A solid dosage form that contains medicinal 
procedures) by its direct application. COATED, substances With or Without suitable diluents and is 
SOLUTION, GEL A solution, Which after usually being administered EXTENDED coated With a thin layer of a Water-insoluble or 
FORMING/DROPS in a drop-Wise fashion, forms a gel. RELEASE Water-soluble polymer; the tablet is formulated in 
SOLUTION, GEL A solution that forms a gel When it comes in such manner as to make the contained medicament 
FORMING, contact With ocular fluid, and Which alloWs at least 20 available over an extended period of time 
EXTENDED a reduction in dosing frequency. folloWing ingestion. 
RELEASE A solution Which is usually administered in a TABLET, FOR A tablet that forms a solution When placed in a 
SOLUTION/ drop-Wise fashion. SOLUTION liquid. 
DROPS TABLET, FOR A tablet that forms a suspension When placed in a 
SUPPOSITORY A solid body of various Weights and shapes, SUSPENSION liquid (formerly referred to as a ‘dispersible 
adapted for introduction into the rectal ori?ce of 25 tablet’). 
the human body; they usually melt, soften, or TABLET, A solid dosage form containing medicinal 
dissolve at body temperature. MULTILAYER substances that have been compressed to form a 
SUPPOSITORY, A drug delivery system in the form of a multiple-layered tablet or a tablet-Within-a-tablet, 
EXTENDED suppository that alloWs for a reduction in dosing the inner tablet being the core and the outer 
RELEASE frequency. portion being the shell. 
SUSPENSION A liquid1 dosage form that contains solid particles 30 TABLET, A solid dosage form containing medicinal 
dispersed in a liquid vehicle. MULTILAYER, substances that have been compressed to form a 
SUSPENSION, A liquid preparation consisting of solid particles EXTENDED multiple-layered tablet or a tablet-Within-a-tablet, 
EXTENDED dispersed throughout a liquid phase in Which the RELEASE the inner tablet being the core and the outer 
RELEASE particles are not soluble; the suspension has been portion being the shell, Which, additionally, is 
formulated in a manner to alloW at least a covered in a designated coating; the tablet is 
reduction in dosing frequency as compared to that 35 formulated in such manner as to alloW at least a 
drug presented as a conventional dosage form reduction in dosing frequency as compared to that 
(e.g., as a solution or a prompt drug-releasing, drug presented as a conventional dosage form. 
conventional solid dosage form). TABLET, A solid dosage form containing medicinal 
SUSPENSION/ A suspension Which is usually administered in a ORALLY substances Which disintegrates rapidly, usually 
DROPS dropWise fashion. DISINTEGRATING Within a matter of seconds, When placed upon the 
SYRUP An oral solution containing high concentrations of tongue. 
sucrose or other sugars; the term has also been 40 TABLET, A solid dosage form containing medicinal 
used to include any other liquid dosage form ORALLY substances Which disintegrates rapidly, usually 
prepared in a sWeet and viscid vehicle, including DIS- Within a matter of seconds, When placed upon the 
oral suspensions. INTEGRATING, tongue, but Which releases a drug (or drugs) at a 
TABLET A solid dosage form containing medicinal DELAYED time other than promptly after administration. 
substances With or Without suitable diluents. RELEASE 
TABLET, A solid dosage form containing medicinal 45 TABLET, A solid dosage form that contains medicinal 
CHEWABLE substances With or Without suitable diluents that is SOLUBLE substances With or Without suitable diluents and 
intended to be cheWed, producing a pleasant possesses the ability to dissolve in fluids. 
tasting residue in the oral cavity that is easily TABLET, SUGAR A solid dosage form that contains medicinal 
sWalloWed and does not leave a bitter or COATED substances With or Without suitable diluents and is 
unpleasant after-taste. coated With a colored or an uncolored Water 
TABLET, A solid dosage form that contains medicinal 50 soluble sugar. 
COATED substances With or Without suitable diluents and is 
covered With a designated coating. Footnotes: 
TABLET, A Solid dosage fon'n containing a conglomerate of 1A liquid is pourable; it ?oyvs and conforms to its container at room temperature. It displays 
COATED medicinal particles that have each been covered glewtf‘mn or pseudqlllasm ?ow. behavnlr' . . 
. . Previously the de?nition ofa lotion Was The term lotion has been used to categorize many 
PARTICLES Wlth a coatlng- topical suspensions, solutions, and emulsions intended for application to the skin.” The 
TABLET, A SOlid dosage form Which releases a drug (or 55 gurrentde?iniition ofa lotion ‘is restricted to an emulsion. I I 
DELAYED drugs) at a tim? other than promptly a?er A semisolid is notpourable; it does not How or conform _to its container atroom temperature. 
RELEASE administration- Enmrimcoamd micl?s an? dday?d ‘It does not ?oW at loW shear stress ‘and generally exhibits plastic ?oW behavior. I 
A colloidal dispersion is a system in Which particles ofcolloidal dimension (i.e., typically 
T616356 dosage forms- betWeen 1 nm and 1 pm) are distributed uniformly throughout a liquid. 
TABLET, A solid dosage fon'n containing a conglomerate of 5Percent Water and volatiles are measured by_ a loss on drying test in Which the sample is 
DELAYED medicinal particles that have been covered With a heated at 1050 C‘ untll Constant Welght 1S achleved' 
RELEASE coating Which releases a drug (or drugs) at a time 
PARTICLES other than promptly after administration. Enteric- 60 
coated articles are delayed release dosage forms. 
TABLET, A tablet that, prior to administration, is intended to EXAMPLE 1 1 
DISPERSIBLE be placed in liquid, Where its contents Will be 
dlsmbut?‘l evenly glroughouf?mt liquid‘ Note: Route of administration. A suitable route of administration 
The term tablet, dispersible is no longer used for _ _ _ _ 
65 for a dosage form containing a pharmaceutically active com approved drug products, and it has been replaced 
by the term ‘tablet, for suspension’. pound of the present invention may be chosen from among 
those listed in Table 11-1. 
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TABLE 1 1-1 -continued 
Routes of administration 
NAME DEFINITION 5 NAME DEFINITION 
BUCCAL Administration directed toWard the cheek, INTRAVITREAL Administration Within the vitreous body of 
generally from Within the mouth. the eye. 
CONIUNCTIVAL Administration to the conjunctiva, the NASAL Administration to the nose; administered 
delicate membrane that lines the eyelids by Way of the nose. 
and covers the exposed surface of the OPHTHALMIC Administration to the external eye. 
eyeball. 10 ORAL Administration to or by Way of the mouth. 
CUTANEOUS Administration to the skin. OROPHARYNGEAL Administration directly to the mouth and 
ENDOSINUSIAL Administration Within the nasal sinuses of pharynx. 
the head. OTHER Administration is different from others on 
ENTERAL Administration directly into the intestines. this list. 
EPIDURAL Administration upon or over the dura PARENTERAL Administration by injection, infusion, or 
mater. 1 5 implantation. 
EXTRACORPOREAL Administration outside of the body. PERCUTANEOUS Administration through the skin. 
HEMODIALYSIS Administration through hemodialysate PERIARTICULAR Administration around a joint. 
fluid. PERIDURAL Administration to the outside of the dura 
INFILTRATION Administration that results in substances mater of the spinal cord.. 
passing into tissue spaces or into cells. PERINEURAL Administration surrounding a nerve or 
INTERSTITIAL Administration to or in the interstices of a nerves. 
tissue. 20 PERIODONTAL Administration around a tooth. 
INTRA-ABDOMINAL Administration Within the abdomen. RECTAL Administration to the rectum. 
INTRA-ARTERIAL Administration Within an artery or arteries. RESPIRATORY Administration Within the respiratory tract 
INTRA-ARTICULAR Administration Within a joint. (INHALATION) by inhaling orally or nasally for local or 
INTRACARTILAGINOUS Administration Within a cartilage; systemic effect. 
endochondral. SOFT TISSUE Administration into any soft tissue. 
INTRACAUDAL Administration Within the cauda equina. 25 SUBCONIUNCTIVAL Administration beneath the conjunctiva. 
INTRACORONARY Administration Within the coronary SUBCUTANEOUS Administration beneath the skin; 
arteries. hypodermic. Synonymous With the term 
INTRADERMAL Administration Within the dermis. SUBDERMAL. 
INTRADUCTAL Administration Within the duct of a gland. SUBLINGUAL Administration beneath the tongue. 
INTRADUODENAL Administration Within the duodenum. SUBMUCOSAL Administration beneath the mucous 
INTRADURAL Administration Within or beneath the dura. 30 membrane. 
INTRAEPIDERMAL Administration Within the epidermis. TOPICAL Administration to a particular spot on the 
INTRAESOPHAGEAL Administration Within the esophagus. outer surface of the body. The EZB term 
INTRAGASTRIC Administration Within the stomach. TRANSMAMMARY is a subset of the 
INTRAGINGIVAL Administration Within the gingivae. term TOPICAL. 
INTRALYMPHATIC Administration Within the lymph. TRANSDERMAL Administration through the dermal layer 
INTRAMEDULLARY Administration Within the marroW cavity 35 of the skin to the systemic circulation by 
ofa bone. diffusion. 
INTRAMENINGEAL Administration Within the meninges (the TRANSMUCOSAL Administration across the mucosa. 
three membranes that envelope the brain 
and spinal cord). 
INTRAMUSCULAR Administration Within a muscle. The foregoing description of the preferred embodiments of 
INTRAOCULAR Admlnlstmtlon Wlthln the W6‘ 40 the present invention have been presented for purposes of 
INTRAOVARIAN Adm1n1strat1on Within the ovary. . . . . . . . 
INTRAPERICARDIAL Administration Within the pericardiwn 1llustrat1on and descnptlon. It 15 not 1ntended to be exhaustlve 
INTRAPERITONEAL Administration Within the peritoneal or to limit the invention to the precise form disclosed. Obvi 
CavltY- I I I I ous modi?cations or variations are possible in light of the 
INTRAPLEURAL Adm1n1strat1on Within the pleura. . . 
INTRAPULMONARY Administration Within the lungs or its above teachlngs' The embodlments Were Chosen and 
bronchi. 45 described to provide the best illustration of the principles of 
INTRASINAL Admlmsmltlon Wlthm the nasal or the invention and its practical application to thereby enable 
periorbital sinuses. . . . . . . . . 
INTRASPINAL Administration Within th? vembml one of ordmary sk1ll 1n the art to ut1l1Ze the 1nvent1on 1n 
column various embodiments and With various modi?cations as are 
INTRASYNOVIAL Agimliliistmtion Within L116 synovial Cavity suited to the particular use contemplated. All such modi?ca 
O a JOmtI 50 . . . . . . . 
INTRATENDINOUS Administration Within a m1 don t1ons and var1at1ons are W1th1n thescope of the 1nvent1on as 
INTRATHECAL Administration Within the cerebrospinal determlned by the appended cla1ms When Interpreted 1n 
fluid at any level of the cerebrospinal axis, accordance With the breadth to Which they are fairly, legally 
including ini?ction into th? Cmbml and equitably entitled. The draWings and preferred embodi 
V?nmcl?s' ments do not and are not intended to limit the ordinary mean 
INTRATHORACIC Administration Within the thorax (internal 55 , , , , , , , , 
to the ribs); Synonymous with the mm mg of the cla1ms 1n the1r fan and broad 1nterpretat1on 1n any 
endothoracic. Way 
INTRATUMOR Administration Within a tumor. 
INTRAUTERINE Administration Within the uterus. \Vhat is ClailnedZ 
INTRAVASCULAR Adm1n1strat1on Within a vessel or vessels. . . 
INTRAVENOUS Administration Within or into a vein or 60 _1: A method of supplemennng a dlet of a mammal’ Com 
veins. PI‘lSlIlgZ 
INTRAVENOUS BOLUS Administration Within or into a vein or administering to said mammal a pharmaceutically effec 
v?ins all at 01m- tive amount of a compound having a chemical formula: 
INTRAVENOUS DRIP Administration Within or into a vein or 
veins over a sustained period of time. R1 
INTRAVENTRICULAR Administration Within a ventricle. 65 R2 / \ R2 
INTRAVE S ICAL Administration Within the bladder. 
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Where R1: Where R2: 
0 
5 
—C—NH—(CH2)n—SR4 or —C—NH—C—CH2—SR4; 
\ ('3 
R3 
/ 
N , 10 
and or 
Where R2: and 
15 Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys 
O O teine, alphadihydrolipoic acid, cystamine, thiolphos 
_C_NH_(CHZ)K_SR4 or _C_NH_C_CH2_SR4 phate, 5'thioladenosine, L-homocysteine, co-enZyme A, 
2-mercaptoethanol, dithiothreitol, iodoacetate, bro 
(I) moacetate, ?uoroacetate or chloroacetate and n:2-4. 
R3 20 11. The method of claim 10, including using oral admin 
3 4 _ istration. 
WheFe R iethyl .Or methyl’ ihydrogen’ glutathlqne’ cys_ 12. The method of claim 10, including administering 
te1ne, alphad1hydrol1po1c ac1d, cystam1ne, thiolphos- . . . 
, - - - betWeen about 0.5 and about 40 milligrams of sa1d compound 
phate, 5 th1oladenos1ne, L-homocysteme, co-enZyme A, k1 f ,d 1, 1 b d _ h d 
2-mercaptoethanol, dithiothreitol, iodoacetate, bro- 25 per 1 Ogram O Sal mamma 5 tom 0 y Welg tper ay' 
moacetate, ?uoroacetate or chloroacetate and n:2-4. 13. The method of claim 10, including using transderrnal 
2. The method of claim 1, including using oral administra- admlmstranon' 
tion. 14. The method of claim 10, including using nasal admin 
3. The method of claim 1, including administering betWeen 30 istration 
about 0-5 and about 40 milligrams Of Said Compound Per 15. The method of claim 10, including using administra 
kilogram of said mammal’s total body Weight per day. tion by Suppository. 
4~_ The method of Claim 1, including using transdermal 16. The method of claim 10, including using intravenous 
adm1n1strat1on. administration 
5} The method of Claim 1’ including using nasal adminis' 35 17. The method of claim 10, including administering said 
tranon' _ _ _ _ _ _ _ compound With a Water soluble metal chelator. 
b 6' The ?ethod of Clalm 1’ lncludmg usmg admlmstranon 18. The method of claim 17, including selecting said Water 
y supposl Ory' _ _ _ _ _ soluble metal chelator from a group consisting of glutathione 
7-_ The method Of 01mm 1, lncludlng 115mg Intravenous 40 (GSH), dihydrolipoic acid (DLPA), lipoic acid (LPA),N-ace 
admlmstranon' tylcysteine (NAC), dimercaptopropane sultanate (DMPS), 
8. The method of claim 1, including administering said dimercaptosuccinic acid (DMSA), ethylenediaminetetraace 
compound With another antiOXidanI- tie acid (EDTA) and mixtures thereof. 
9. The method of claim 1. including selecting said antioxi- 19_ A method Of relieving Oxidative Stress in a mammal, 
dant from a list of antioxidants consisting of Vitamin-E, Vita- 45 Comprising. 
min-D, cysteine, glutathione, lipoic acid and combinations _ _ _ _ _ 
thereof adm1n1stering to sa1d mammal a pharmaceutically effec 
10' A method to remove heavy metals and toxins from a t1Ve amount of a compound having a chemical formula: 
mammal, comprising: 
administering to said mammal a pharmaceutically effec- 50 l 
tiVe amount of a compound having a chemical formula: R2/R\ R2 
1 
R2/R\ R2 
55 Where R1: 
Where R1: 
60 
\ \ 
/ 
N/ , 65 N , 
US 8,426,368 B2 
37 
Where R2: 
0 
0 
and 
Where R3 :ethyl or methyl, R4:hydrogen, glutathione, cys 
teine, alphadihydrolipoic acid, cystamine, thiolphos 
phate, 5'thioladenosine, L-homocysteine, co-enZyme A, 
2-mercaptoethanol, dithiothreitol, iodoacetate, bro 
moacetate, ?uoroacetate or chloroacetate and n:2-4. 
20. The method of claim 19, including using oral admin 
istration. 
21. The method of claim 19, including administering 
betWeen about 0.5 and about 100 milligrams of said com 
pound per kilogram of said mammal’s total body Weight per 
day. 
22. The method of claim 19, including using transderrnal 
administration. 
23. The method of claim 19, including using nasal admin 
istration. 
24. The method of claim 19, including using administra 
tion by suppository. 
25. The method of claim 19, including using intravenous 
administration. 
26. The method of claim 19, including administering said 
compound With a precursor of glutathione, 
27. The method of claim 26, including selecting said pre 
cursor of glutathione from a group consisting of cysteinc, 
N-acetylcysteine, glycine, glutamate and combinations 
thereof. 
28. The method of claim 19, including administering said 
compound With a dietary supplement that supports glu 
tathione synthesis. 
29. The method of claim 28, including selecting said 
dietary supplement from a group consisting of Whey protein, 
N-acetylcysteine, cysteine, glutathione, nicotine adenine 
dinucleotide (NAD+), reduced nicotine adenine dinucleotide 
(NADH), glycylcysteine (gly-cys), glutamylcysteine (glu 
cys), and combinations thereof. 
30. A pharmaceutical composition, comprising: 
a pharmaceutically effective amount of a compound hav 
ing a chemical formula: 
Where R1: 
/ 
10 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
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Where R2: 
O O 
0 
and 
Where R3Iethyl or methyl, R4 hydrogen, glutathione, cys 
teine, alphadihydrolipoie acid, cystamine, thiolphos 
phate, 5'thioladenosine, L-homocysteine, co-enZyme A, 
2-mercaptoethanol, dithiothreitol, iodoacetate, bro 
moacetate, ?uoroacetate or chloroacetate and n:2-4; 
and 
a pharmaceutically acceptable excipient. 
31. The composition of claim 30, Wherein said excipient is 
selected from a group of materials consisting of Acacia, 
Acesulfame Potassium, Acetic Acid, Acetone, Acetyltributyl 
Citrate, Acetyltr‘iethyl Citrate, Agar, Albumin, Alcohol, Alg 
inic Acid, Aliphatic Polyesters, Alitame, Almond Oil, Alpha 
Tocopherol, Aluminum Hydroxide Adjuvant, Aluminum 
Oxide, Aluminum Phosphate Adjuvant, Aluminum Stearate, 
Ammonia Solution, Ammonium Alginate, Ascorbic Acid, 
Ascorbyl Palmitate, Aspartame, Attapulgite, Bentonite, Ben 
Zalkonium Chloride, BenZethonium Chloride, BenZoic Acid, 
BenZyl Alcohol, BenZyl BenZoate, Bor‘ic Acid, Bronopol, 
Butylated Hydroxyanisole, Butylated Hydroxytoluene, 
Butylparaben, Calcium Alginate, Calcium Carbonate, Cal 
cium Phosphate, Dibasic Anhydrous, Calcium Phosphate, 
Dibasic Dihydrate, Calcium Phosphate, Tribasic, Calcium 
Stearate, Calcium Sulfate, Canola Oil, Carbomer, Carbon 
Dioxide, Carboxymethylcellulose Calcium, Carboxymethyl 
cellulose Sodium, Carrageenan, Castor Oil, Hydrogenated 
Castor Oil, Cellulose, Microcrystalline, Cellulose, PoW 
dered, Cellulose, Silici?ed Microcrystalline, Cellulose 
Acetate, Cellulose Acetate Phthalate, Ceratonia, Cetostearyl 
Alcohol, Cetrimide, Cetyl Alcohol, Cetylpyridinium Chlo 
ride, Chitosan, Chlorhexidine, Chlorobutanol, Chlorocresol, 
Chlorodi?uoroethane (HCFC), Chloro?uorocarbons (CFC), 
Chloroxylenol, Cholesterol, Citric Acid Monohydrate, Col 
loidal, Silicon Dioxide, Coloring Agents, Copovidone, Com 
Oil, Cottonseed Oil, Cresol, Croscar'mellose Sodium, 
Crospovidone, Cyclodextr‘ins, Cyclomethicone, Denatonium 
BenZoate, Dextrates, Dextrin, Dextrose, Dibutyl Phthalate, 
Dibutyl Sebacate, Diethanolamine, Diethyl Phthalate, Dif 
luoroethane (HFC), Dimethicone, Dimethyl Ether, Dimethyl 
Phthalate, Dimethyl Sulfoxide, Dimethylacetamide, Diso 
dium Edetate, Docusate Sodium, Edetic Acid, Erythorbic 
Acid, Erythritol, Ethyl Acetate, Ethyl Lactate, Ethyl Maltol, 
Ethyl Oleate, Ethyl Vanillin, Ethylcellulose, Ethylene Glycol 
Palmitostearate, Ethylene Vinyl Acetate, Ethylparaben, Fruc 
tose, Fumar‘ic Acid, Gelatin, Glucose, Glycerin, Glyceryl 
Behenate, Glyceryl Monooleate, Glyceryl Monostearate, 
Glyceryl Palmitostearate, Glycofurol, Guar Gum, Hector‘ite, 
Hepta?uoropropane (HFC), Hexetidine, Hydrocarbons 
(HC), Hydrochlor‘icAcid, Hydroxyethyl Cellulose, Hydroxy 
ethylmethyl Cellulose, Hydroxypropyl Cellulose, Hydrox 
ypropyl Cellulose, LoW-substituted, Hydroxypropyl Starch, 
Hypromellose, Hypromellose Acetate Succinate, Hypromel 
lose Phthalate, lmidurea, lnulin, Iron Oxides, lsopropylAlco 
hol, lsopropyl Myr‘istate, lsopropyl Palmitate, Kaolin, Lactic 
Acid, Lactitol, Lactose Anhydrous, Lactose Monohydrate, 
Lactose Spray-Dried, Lanolin, Lanolin Hydrous, Lanolin 
Alcohols, Lauric Acid, Lecithin, Leucine, Linoleic Acid, 
Macrogol l5 Hydroxystearate, Magnesium Aluminum Sili 
cate, Magnesium Carbonate, Magnesium Oxide, Magnesium 
Silicate, Magnesium Stearate, Magnesium Trisilicate, Malic 
Acid, Maltitol, Maltitol Solution, Maltodextr‘in, Maltol, Mal 
tose, Mannitol, Mediumchain Triglycerides, Meglumine, 


